

Marc Buyse

SECTION A: INDIVIDUAL INFORMATION

A.1. Personal information

Name	Marc Buyse
Post or Position	Chariman, IDDI Inc.
Employer, Research Institution or Affiliation	IDDI (International Drug Development Institute) Inc. 363 N. Sam Houston Parkway East Suite 1100 Houston, TX 77060

A.2. Short Biography

Marc Buyse holds degrees from Brussels University (Belgium), the Cranfield School of Management (UK) and a ScD in biostatistics from the Harvard School of Public Health (USA). Prior to founding the International Drug Development Institute (IDDI) in 1991, he had worked for 12 years at the EORTC in Brussels and for two years at the Dana Farber Cancer Institute in Boston. He is also the founder of CluePoints, a company dedicated to statistical monitoring of clinical trials. He has held board positions in several statistical societies and is Associate Professor of biostatistics at the Limburgs Universitair Centrum, Diepenbeek, Belgium. His research interests include clinical trial design, validation of biomarkers and surrogate endpoints, randomization techniques, statistical methods in oncology, statistical detection of errors and meta-analysis (<http://publicationslist.org/marc.buyse>).

SECTION B: DISCLOSURES

B.1. Financial Interests

Please provide information on financial interests that could be perceived to influence the responsibilities and decision making process of the Independent Panel. This should include financial relationships with GSK and other pharmaceutical or biotechnology companies within the last three years. It should include:

- *Board memberships*
 - No such activity in a personal capacity. See “employment” for such activities through IDDI.
- *Consultancies*
 - No such activity in a personal capacity. See “employment” for such activities through IDDI.
- *Employments*
 - IDDI activities within the last three years included consultancy, paid lectures, Data Monitoring Committee membership, and Steering Committee membership for trials conducted or sponsored by the following companies: Ablynx, Actelion, Allos, Amgen, Aveo, AstraZeneca, Biothera, Bristol-Myers Squibb, Cell Therapeutics, Celgene, Cerulean, Cyclacel, Debiopharm, Dendreon, Endocyte, Epicept, Genentech, Genoptix, Gilead, GMP-Orphan, GSK, Helsinn, Imclone, Imcyse, Immunogen, Immunovaccine, Innate, IRX Therapeutics, Kiadis, Lilly, Merck, Micromet, Molecular Partners, Mologen, Monogram,

Mundipharma, Neovacs, Nordic, Novartis, Onyx, Oasmia, Oncothyreon, Ophthotech, Oraya, Orthobiotech, Panoptica, Pfizer, Prostrakan, Roche, Sanofi-Aventis, Santen, Steba, Synta, Synhthon, Tarsa, Tetralogic, Teva, Transgene Wyeth and YM Biosciences. None of these activities was directly or indirectly related to GSK's data sharing project.

- *Grants/grants pending*
 - GSK awarded an unrestricted grant of EUR 55,500 to IDDI in 2008 to perform a meta-analysis of all randomized trials in metastatic renal cell carcinoma. This meta-analysis is not directly or indirectly related to GSK's data sharing project.
- *Patents (planned, pending or issued)*
 - US Patent Pending on central statistical monitoring, Number 13/452,338. This patent is not directly or indirectly related to GSK's data sharing project.
- *Royalties*
 - None
- *Stocks or shares (including options)*
 - Stock in Clinimetrics S.A., the parent company of IDDI S.A., CluePoints S.A. and CluePoints Inc. None of these companies is directly or indirectly involved in GSK's data sharing project.

B.2 Other Real or Potential Conflicts of Interest

Please provide any other (e.g. non-financial) real or potential conflicts of interest that could be perceived to influence the responsibilities and decision making process of the Independent Panel. For example potential biases based on pre-existing personal views, academic or commercial competition, personal relationships or institutional affiliations.

Answer: No other conflict of interest to report.